Robbins Geller Rudman & Dowd LLP has launched an investigation into GRAIL, Inc. for potential violations of U.S. federal securities laws. The investigation follows GRAIL's announcement on February 19, 2026, that its NHS-Galleri trial failed to meet its primary endpoint of statistically significant Stage III-IV cancer reduction, causing the stock price to fall significantly.

The Supreme Court ruled 6-3 that President Trump's sweeping global tariffs were unconstitutional, finding that the International Emergency Economic Powers Act does not authorize the president to impose tariffs without clear congressional authorization. The decision triggered a sharp rally across U.S. equities, with 10 stocks posting significant gains following the ruling that invalidates tariffs that had reached up to 145% on some products.

U.S. stock futures rose on Friday ahead of Q4 GDP data and PCE inflation gauge releases. Markets are pricing in a 94% likelihood of unchanged Fed rates in March. Notable movers include Copart missing earnings expectations, Comfort Systems raising dividends, Grail plunging 47% on weak earnings, Candel Therapeutics declining on stock offering announcement, and Dropbox falling despite beating earnings. Wells Fargo strategist recommends leaning into growth-sensitive sectors like Financials and Industrials rather than defensive positioning.

Grail's stock surged 13% following optimism about its Galleri multi-cancer early detection test. The company projects 22-32% revenue growth for 2026 and plans to submit for FDA premarket approval in Q1 2026, which could unlock medical coverage and boost adoption. With $904 million in cash and improving burn rates, management believes it has runway through 2030.

The global Minimal Residual Disease (MRD) Testing Market is projected to reach $4.50 billion by 2030, with a 10.1% CAGR, driven by increasing cancer diagnostic needs and personalized medicine approaches.

Quest Diagnostics reported strong Q1 2025 results, with revenue and earnings beating estimates. The company reaffirmed its full-year guidance and announced strategic acquisitions and partnerships, fueling confidence in its outlook.

Jim Cramer recommends buying GRAIL and considers Healthpeak Properties a 'reasonable' REIT. He also discusses his views on other healthcare and technology stocks.

The global cancer therapy market is expected to grow significantly, driven by advancements in cancer detection and treatment technologies. Several biotech companies, including Oncolytics Biotech, GRAIL, Quest Diagnostics, Renovaro, and Predictive Oncology, have made notable progress in their respective cancer-focused initiatives.

The European Court of Justice ruled in favor of Illumina, stating that the European Commission exceeded its authority by asserting jurisdiction over Illumina's acquisition of GRAIL. The $476.96 million fine will no longer be payable, and the U.S. FTC also dismissed the case against Illumina and GRAIL.